Abstract. The high frequency of prevalence and the decrease in the quality of life of patients determine the urgency of studying the peculiarities of the etiology and pathogenesis of inflammatory bowel diseases. The difficulty of finding new non-invasive markers lies in the lack of a clear understanding of the molecular mechanisms of the pathogenesis of these diseases. One of the promising directions in the diagnosis of chronic inflammatory diseases is the identification of specific miRNA molecules in blood serum, which act as powerful negative regulators of gene expression.

Article received: 19.01.2024

Ключові слова: Crohn’s disease, nonspecific ulcerative colitis, pathogenesis, diagnosis, miRNA

Повний текст: PDF (Ukr)

1. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015; 12(12):720-7.doi.org/10.1038/nrgastro.2015.150
2. Радченко ОМ. Сучасні підходи до діагностики та лікування запальних хвороб товстої кишки в практиці лікаря загальної практики. З Здоров'я України. 2021; 8(501): 53-7.doi.org/health-ua.com/article/65633-suchasn-pdhodi-do-dagnostiki-talkuvannya-zapalnih-hvorob--tovsto-kishki-v-p
3. Наказ МОЗ України від 6 жовтня 2023 р. № 1742: Уніфікований клінічний протокол первинної та спеціалізованої медичної допомоги запальні захворювання кишечника (хвороба крона, виразковий коліт).moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-06102023--1742-pro-zatverdzhennja-unifikovanogo-klinichnogo-protokolu-pervinnoi-ta-specializovanoi-medichnoi-dopomogi-zapalni-zahvorjuvannja-kishechnika-hvoroba-krona-virazkovij-kolit
4. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017; 389: 1741-55.doi.org/10.1016/S0140-6736(16)31711-1
5. Cahana I, Iraqi FA. Impact of host genetics on gut microbiome: Take-home lessons from human and mouse studies. Animal Model Exp Med. 2020; 3: 229-36.doi.org/10.1002/ame2.12134
6. Ishfaq Ah., Badal C. R., Salman A. Kh., Septer S., Shahid U. Microbiome, Metabolome and Inflammatory Bowel Disease. Microorganisms. 2016; 4(20): 19.doi.org/10.3390/microorganisms4020020
7. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015; 12(4): 205-17. doi: 10.1038/nrgastro.2015.34.doi.org/10.1038/nrgastro.2015.34
8. M'Koma AE. The Multifactorial Etiopathogeneses Interplay of Inflammatory Bowel Disease: An Overview. Gastrointest. Disord. 2019; 1(1): 75-105.doi.org/10.3390/gidisord1010007
9. Qiu P, Ishimoto Е, Fu L, Zhang J, Zhang Z, Liu Y, et al. The Gut Microbiota in Inflammatory Bowel Disease. Frontiers in Cellular and Infection Microbiology. 2022; 12: 733992 - 14.doi.org/10.3389/fcimb.2022.733992
10. Мартишин О.О. Запальні та функціональні захворювання кишечника: вплив і корекція кишкової мікрофлори. Укр Мед Часопис. 2019; 2(1):9-10.
11. Palmela C, Chevarin C, Zhilu Xu, Torres J, Sevri G, Hirten R, et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut. 2019; 67(3): 574-87.doi.org/10.1136/gutjnl-2017-314903
12. Birimberg-Schwartz L, Wilson DC, Kolho KL, Karolewska-Bochenek K, Afzal NA, Spray C, Romano C, Lionetti P, et al. pANCA and ASCA in Children with IBD-Unclassified, Crohn's Colitis, and Ulcerative Colitis-A Longitudinal Report from the IBD Porto Group of ESPGHAN. Inflamm Bowel Dis. 2016; 22(8): 1908-14.doi.org/10.1097/MIB.0000000000000784
13. Andersen V, Chan S, Luben R, Kay-Tee Khaw, Olsen А, Tjonneland А, et al. Fibre intake and the development of inflammatory bowel disease: A European prospective multicentre cohort study (EPIC-IBD). Journal of Crohn's and Colitis. 2018; 12(2):129-36.doi.org/10.1093/ecco-jcc/jjx136
14. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016; 27(16): 341-52.doi.org/10.1038/nri.2016.42
15. Michaudel C, Sokol H. The Gut Microbiota at the Service of Immunometabolism. Cell Metabolism. 2020; 32(4): 514-23.doi.org/10.1016/j.cmet.2020.09.004
16. Almradi А, Hanzel J, Sedano R, Parker CE, Feagan BG, Ma C, et al. Clinical Trials of IL-12/IL-23 Inhibitors in Infammatory Bowel Disease. BioDrugs. 2020; 34(6): 713-21.doi.org/10.1007/s40259-020-00451-w
17. Fanizza J, Lusetti F, Fasulo E, Allocca M, Furfaro F, Zilli A, et al. The Role of IL-23 Inhibitors in Crohn's Disease. J. Clin Med. 2024; 13(1):224.doi.org/10.3390/jcm13010224
18. Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023; 20: 433-46.doi.org/10.1038/s41575-023-00768-1
19. Shapiro JM, de Zoete MR, Palm NW, Laenen Y, Bright R, Mallette M, et al. Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease. Cell Host Microbe. 2021;29(1):83-93.e3.doi.org/10.1016/j.chom.2020.12.003
20. Cromer WE, Mathis JM, Granger DN, Chaitanya GV, Alexander JS. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol. 2011;17(5): 578-93.doi.org/10.3748/wjg.v17.i5.578
21. Lugonja SI, Pantic IL, Milovanovic TM, Grbovic VM, Djokovic BM, Todorovic ŽD, et al. Atherosclerotic Cardiovascular Disease in Inflammatory Bowel Disease: The Role of Chronic Inflammation and Platelet Aggregation. Medicina. 2023: 59: 554.doi.org/10.3390/medicina59030554
22. Al-Sulaiman RM., Mona IH, Yasawy MI, Al-Ateeq SA, Abdelrashid MM, Hussameddin AM, et al. Association of NOD2/CARD15, DLG5, OCTN1 and Toll-Like Receptor 4 Gene Polymorphisms with Inflammatory Bowel Disease. A University Hospital Experience. Saudi Journal of Medicine and Medical Sciences. 2014; 2(2):81-5.doi.org/10.4103/1658-631X.136988
23. Torres JC, Gomes C, Jensen CB, Agrawal M, Ribeiro-Mourão F, Jess T, et al. Risk factors for developing inflammatory bowel disease within and across families with a family history of IBD. J Crohns Colitis. 2023;17(1): 30-36.doi.org/10.1093/ecco-jcc/jjac111
24. Krishnachaitanya SS, Liu M, Fujise K, Li Q. MicroRNAs in Inflammatory Bowel Disease and Its Complications. Int J Mol Sci. 2022;23(15):8751.doi.org/10.3390/ijms23158751
25. Wu F, Zhang S, Dassopoulos T, Harris ML, Bayless TM, Meltzer SJ, et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflamm Bowel Dis. 2010;16(10): 1729-38.doi.org/10.1002/ibd.21267
26. Wang JY, Cui YH, Xiao L, Chung HK, Zhang Y, Rao JN, et al. Regulation of Intestinal Epithelial Barrier Function by Long Noncoding RNA uc.173 through Interaction with MicroRNA 29b. Mol Cell Biol. 2018;38(13):e00010-18.doi.org/10.1128/MCB.00010-18
27. Schaefer JS, Attumi T, Opekun AR, Abraham B, Hou J, Shelby H, et al. MicroRNA signatures differentiate Crohn's disease from ulcerative colitis. BMC Immunol. 2015;16:5.doi.org/10.1186/s12865-015-0069-0
28. Guz M, Dworzański T, Jeleniewicz W, Cybulski M, Kozicka J, Stepulak A, et al. Elevated miRNA Inversely Correlates with E-cadherin Gene Expression in Tissue Biopsies from Crohn Disease Patients in contrast to Ulcerative Colitis Patients. Hindawi BioMed Research International. 2020;(8, Article e0159956):1-7.doi.org/10.1155/2020/4250329
29. Hang H, Chao K, Ng SC, Bai AH, Yu Q, Yu J, et al. Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease. Genome Biol. 2016;17:58.doi.org/10.1186/s13059-016-0901-8
30. Suri K, Bubier JA, Wiles MV, Shultz LD, Amiji MM, Hosur V. Role of MicroRNA in Inflammatory Bowel Disease: Clinical Evidence and the Development of Preclinical Animal Models. Cells. 2021; 10(9): 2204.doi.org/10.3390/cells10092204
31. Masi L, Capobianco I, Magrì C, Marafini I, Petito V, Scaldaferri F. MicroRNAs as Innovative Biomarkers for Inflammatory Bowel Disease and Prediction of Colorectal Cancer. Int J Mol Sci. 2022; 23: 7991.doi.org/10.3390/ijms23147991
32. Jeremy S. Schaefer miRNAs: how many in IBD? Curr Opin Gastroenterol. 2016;32(4):258-266.doi.org/10.1097/MOG.0000000000000284
33. Alamdari-Palangi V, Vahedi F, Shabaninejad Z, Dokeneheifard S, Movehedpour A, Taheri-Anganeh M, et al. MicroRNA in inflammatory bowel disease at a glance. European Journal of Gastroenterology & Hepatology. 2021; 33(2): 140-48.doi.org/10.1097/MEG.0000000000001815
34. Wang H, Zhang S, Yu Q, Yang G, Guo J, Li M, et al. Circulating MicroRNA223 is a New Biomarker for Inflammatory Bowel Disease. Medicine. 2016;95 (5): e2703.doi.org/10.1097/MD.0000000000002703
35. Neudecker V, Haneklaus M, Jensen O, Khailova L, Masterson JC, Tye H, et al. Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. J Exp Med. 2017;214(6):1737-52.doi.org/10.1084/jem.20160462
36. Fujioka S, Nakamichi I, Asano K, Matsumoto T, Kitazono T, et al. Serum microRNA levels in patients with Crohn's disease during induction therapy by infliximab. Gastroenterology and Hepatology. 2014;29(6): 1207-14.doi.org/10.1111/jgh.12523
37. Kalla R, Ventham NT, Kennedy NA, Quintana JF, Nimmo ER, Buck AH, et al. MicroRNAs: new players in IBD. Gut. 2015; 64(3):504-17.doi.org/10.1136/gutjnl-2014-307891